Intervention without implantation! Xinzhi medical innovative research and development of coronary drug balloon can effectively solve the pain points of traditional stent surgery

Author: Xu Wenjuan: "intervention without implantation is a clinical trend I believe that the growth rate of drug balloon will exceed that of cardiac stent in the future." Sheng Weiwen, who has 15 years of experience in the research and development of cardiovascular products, commented Cardiovascular disease has become a major disease threatening the health of Chinese people Coronary heart disease is very common in cardiovascular diseases, and its incidence rate is increasing year by year In 2018, there were more than 900000 cases of PCI in China, with a year-on-year growth of about 21.5%, and a compound growth rate of 16.7% from 2009 to 2018, with an overall accelerated growth momentum In the coronary intervention, stent implantation is the main treatment for coronary artery stenosis There are data disclosure, stent implantation accounted for nearly 90% There are millions of stents implanted each year Although coronary stenting is the mainstream treatment, it also has some defects For example, the risk of stent embolism and bleeding, the risk of restenosis in stent and the prognosis is not satisfactory Are there any other treatment options that can help improve this situation? Sheng Weiwen, founder of Shanghai Xinzhi Medical Technology Co., Ltd (hereinafter referred to as "Xinzhi medical"), told aowang that the drug balloon developed by the company will bring new possibilities for coronary intervention treatment Opportunity: drug balloon is expected to become one of the representative treatment schemes of "intervention without implantation" In 2016, Sheng Weiwen, who has been engaged in the research and development of cardiovascular products in domestic famous enterprises, found a new treatment scheme for coronary intervention - drug balloon market opportunity "It can be said that the drug balloon is expected to become one of the representative treatment schemes of" intervention without implantation "in the coronary intervention surgery." Said Sheng Weiwen Drug balloon, as a non stent treatment technology, is widely used in the fields of coronary artery and lower extremity artery It can inhibit intimal hyperplasia by releasing anti proliferative drugs to the arterial wall Sheng Weiwen said that the appearance of drug balloon can reduce the use of stent and increase the long-term prognosis of patients "With its safety and effectiveness, the drug balloon has been recognized by doctors at home and abroad We found that there are few products of coronary drug saccules in the domestic market, while the price of imported coronary drug saccules is generally expensive, and there are not many patients who use them " Said Sheng Weiwen At that time, he said, there was only one balloon for coronary drugs on the market, which was still from abroad It can be seen that there is a large space for "localization" of coronary drug balloon Compared with the traditional stent surgery, the biggest characteristic of drug balloon is no implant, which greatly reduces the clinical risk of using the traditional stent and makes up for the shortcomings of the original treatment In general, patients need to take anticoagulants for life after stent implantation, while drug saccules usually only need anticoagulant treatment for one month because of the obvious characteristics of no implants, which brings great security and convenience to patients Compared with the blank market, the clinical effect of the product is better In 2017, Sheng Weiwen made up his mind to start to set up a technical team and successfully created "heart to health" He said that Xinzhi medical is a high-tech enterprise specializing in the research and development of medical devices, which is committed to the research and development of cardiovascular and peripheral vascular interventional medical devices, including the research and development of coronary drug balloon, which is of great concern "Xinzhi medical focuses on the research and development of drug saccules, aiming to create a domestic drug saccule with excellent quality and reasonable price through our own technical advantages, so as to benefit more patients." Said Sheng Weiwen More than 200 patients have been treated, and the clinical effect is comparable to or even better than that of foreign products After half a year's efforts in research and development, Xinzhi medical has launched a drug-eluting balloon catheter, a drug-eluting balloon product for coronary artery The drug-eluting balloon catheter developed by Xinzhi Medical Co., Ltd is mainly composed of paclitaxel drug coating and balloon catheter The balloon dilating catheter is pushed to the lesion through the guide wire, and the contrast medium is injected along the catheter cavity to make the balloon expand to a certain extent, dilate the narrow or occluded vessels and maintain for a period of time The drug on the balloon (paclitaxel) can be fully, rapidly and evenly released to the local vascular wall, inhibit the intimal hyperplasia of vascular smooth muscle, restore the blood supply of the distal vessels, and avoid the formation of thrombus "The drug release time only needs 30-60 seconds When all the drugs are released, the balloon and catheter are removed from the body without any implants The whole treatment process is simple and efficient." Sheng Weiwen said (product chart) he introduced that Xinzhi medical's drug-eluting balloon catheter product has multiple advantages in design First of all, this kind of coronary drug balloon adopts multilayerptx coating technology, with uniform coating, which can effectively reduce the loss of drugs in the delivery process and improve the transfer rate of drugs to the blood vessel wall Secondly, the design of the balloon catheter is exquisite, and the manipulation and passing ability are very good (product chart) in addition, it can also achieve a very small particle size to ensure that more drugs are in contact with the vessel wall, absorbed by the vessel wall, and the distal small vessels are not blocked Sheng Weiwen pointed out that compared with similar foreign products "Xinzhi's products have been greatly improved." Sheng Weiwen said that at present, the product has started clinical trials in more than ten well-known hospitals in China, and the progress is very smooth (product drawing) Professor Tao Ling, chief physician of Cardiology Department of Xijing Hospital, vice chairman of Cardiology Department of the military medical science and Technology Committee, member of American Society for angiocardiography and intervention (SCAI) and chief researcher of drug balloon, once said: "based on the experience of previous generation products of foreign companies, Xinzhi medical uses new design and processing technology to make the application of drug balls The drug transfer efficiency is further improved on the basis of ensuring the push performance At present, the pre marketing confirmatory clinical research is coming to an end In the future, the products will enrich doctors' clinical treatment options after they are launched on the market! " Sheng Weiwen told arteria.com that Xinzhi medical's drug balloon products have completed more than 200 clinical cases and are undergoing postoperative follow-up According to the existing data, the clinical effect is very good Not only this product, but several other products developed by Xinzhi medical are also outstanding For example, the fistula medicine saccule can solve the problems of narrow and occluded hemodialysis pathway for hemodialysis patients; the vibration saccule can provide practical solutions for severe calcification of peripheral artery; the spinous process saccule can provide optimized solutions for the pretreatment of blood vessels before the placement of medicine saccule and medicine stent The research and development of these products meet more clinical indications, help doctors deal with complex and diverse diseases, and inject new energy into cardiovascular interventional therapy Insisting on innovation, Xinzhi medical has applied for 14 domestic patents and 2 PCT patents In addition, it has also won the favor of founder, Hesheng, Chende capital and other investment institutions, and successfully obtained two rounds of financing, with the amount of financing reaching tens of millions Jeni turtle